natgillin/translations-raw huggingface dataset:
Doravirin udviste antiviral aktivitet mod et bredt panel af primære hiv-1-isolater (A, A1, AE, AG, B, BF, C, D, G, H) med EC50-værdier fra 1,2 nM til 10,0 nM. Doravirins antivirale aktivitet var ikke antagonistisk ved kombination med lamivudin og tenofovirdisoproxil. 
Doravirine demonstrated antiviral activity against a broad panel of primary HIV-1 isolates (A, A1, AE, AG, B, BF, C, D, G, H) with EC50 values ranging from 1.2 nM to 10.0 nM.
I et studie af peri- og postnatal toksicitet reducerede tenofovirdisoproxil imidlertid levedygtighedsindekset og vægten hos afkom ved maternelt toksiske doser. 
However, tenofovir disoproxil reduced the viability index and weight of pups in a peri-postnatal toxicity study at maternally toxic doses.
Der er ikke klarlagt et breakpoint for reduktion i følsomhed forårsaget af forskellige NNRTI-substitutioner, der er forbundet med reduktion i klinisk virkning (se pkt. 
A breakpoint for a reduction in susceptibility, yielded by various NNRTI substitutions, that is associated with a reduction in clinical efficacy has not been established (see section 5.1).
Samtidig administration af doravirin/lamivudin/tenofovirdisoproxil og lægemidler, der er CYP3Ahæmmere, kan resultere i en øget plasmakoncentration af doravirin. 
Co-administration of doravirine/lamivudine/tenofovir disproxil and medicinal products that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine.
Doravirin/lamivudin/tenofovirdisoproxil må ikke administreres sammen med lægemidler, der er potente CYP3A-enzyminduktorer, da der forventes at forekomme et signifikant fald i plasmakoncentrationen af doravirin, hvilket kan nedsætte doravirin/lamivudin/tenofovirdisoproxils virkning (se pkt. 
Doravirine/lamivudine/tenofovir disoproxil should not be co-administered with medicinal products that are strong CYP3A enzyme inducers as significant decreases in doravirine plasma concentrations are expected to occur, which may decrease the effectiveness of doravirine/lamivudine/tenofovir disoproxil (see sections 4.3 and 5.2).
Alle patienter med hiv-1 skal testes for tilstedeværelse af hepatitis B-virus (hbv), før antiretroviral behandling initieres. 
Severe acute exacerbation of hepatitis B in patients co-infected with HIV-1 and HBV All patients with HIV-1 should be tested for the presence of hepatitis B virus (HBV) before initiating antiretroviral therapy.
2.185 (12%) ng·t/ml hos forsøgspersoner med CrCl > 80 ml/min til henholdsvis 3.064 (30%) ng·t/ml, 6.009 (42%) ng·t/ml og 15.985 (45%) ng·t/ml hos forsøgspersoner med let nedsat, moderat nedsat og svært nedsat nyrefunktion. 
Compared with subjects with normal renal function, the mean (% CV) tenofovir exposure increased from 2,185 (12 %) ng·h/mL in subjects with CrCl > 80 mL/min to respectively 3,064 (30 %) ng·h/mL, 6,009 (42 %) ng·h/mL and 15,985 (45 %) ng·h/mL in subjects with mild, moderate, and severe renal impairment.
Doravirin/lamivudin/tenofovirdisoproxil må ikke administreres sammen med andre lægemidler, der indeholder lamivudin, eller sammen med lægemidler, der indeholder tenofovirdisoproxil eller tenofoviralafenamid, eller sammen med adefovirdipivoxil (se pkt. 
Doravirine/lamivudine/tenofovir disoproxil must not be co-administered with other medicinal products containing lamivudine, or with medicinal products containing tenofovir disoproxil, or tenofovir alafenamide, or with adefovir dipivoxil (see section 4.5).
I in vitro-studier var doravirin ved klinisk relevante koncentrationer i stand til at undertrykke følgende NNRTI-associerede substitutioner: K103N, Y181C og G190A. 
In in vitro studies, doravirine was able to suppress the following NNRTI-associated substitutions; K103N, Y181C, and G190A under clinically relevant concentrations.
I en in vivo-musemikronukleusanalyse var tenofovirdisoproxil negativt, når det blev administreret til hanmus. 
In an in vivo mouse micronucleus assay, tenofovir disoproxil was negative when administered to male mice.
Indvirkning på lægemiddelniveauer Geometrisk gennemsnitsratio (90% CI)* 
Geometric Mean Ratio (90 % CI)*
Tabel 2: Tabel over bivirkninger associeret med doravirin/lamivudin/tenofovirdisoproxil 
Table 2: Tabulated summary of adverse reactions associated with doravirine/lamivudine/tenofovir disoproxil
Doravirin/lamivudin/tenofovirdisoproxil må ikke administreres sammen med doravirin, medmindre det er nødvendigt for dosisjustering (f.eks. med rifabutin) (se pkt. 
Doravirine/lamivudine/tenofovir disoproxil should not be administered with doravirine unless needed for dose adjustment (e.g., with rifabutin) (see sections 4.2 and 4.5).
Andre lægemidlers indvirkning på doravirin, lamivudin og tenofovirdisoproxil 
Effects of other medicinal products on doravirine, lamivudine, and tenofovir disoproxil Doravirine
Autoimmune sygdomme (f.eks. Graves sygdom, autoimmun hepatitis, polymyositis og Guillain-Barrés syndrom) er også rapporteret at forekomme ved immunreaktivering. 
Autoimmune disorders (such as Graves' disease, autoimmune hepatitis, polymyositis, and GuillainBarré syndrome) have also been reported to occur in the setting of immune reactivation; however, the time to onset is more variable and can occur many months after initiation of treatment.
Syrereducerende midler antacidum (aluminium- og magnesiumhydroxid, oral suspension) (20 ml enkeltdosis, doravirin 100 mg enkeltdosis) 
Acid-Reducing Agents antacid (aluminium and magnesium hydroxide oral suspension) (20 mL SD, doravirine 100 mg SD)
• træthedsfølelse, feber. 
• feeling tired, fever
Delstrigo virker ved at hæmme hiv-virusets evne til at formere sig (lave kopier af sig selv) i kroppen. 
Delstrigo works by preventing HIV from making more viruses in your body.
Delstrigo 100 mg / 300 mg / 245 mg filmovertrukne tabletter doravirin/lamivudin/tenofovirdisoproxil 
Delstrigo 100 mg / 300 mg / 245 mg film-coated tablets doravirine/lamivudine/tenofovir disoproxil
Doravirin, lamivudin og tenofovirdisoproxils indvirkning på andre lægemidler 
Effects of doravirine, lamivudine, and tenofovir disoproxil on other medicinal products Doravirine
Delstrigo skal seponeres, hvis den estimerede CrCl falder til under 50 ml pr. minut (se pkt. 
Delstrigo should be discontinued if estimated CrCl declines below 50 mL per minute (see section 4.4).
Ikke almindelig myalgi, artralgi, rabdomyolyse* muskelsvaghed* 
Uncommon myalgia, arthralgia, rhabdomyolysis* muscular weakness*
Observerede aminosyresubstitutioner i RT omfattede: V106A, V106M, V106I, V108I, F227L, F227C, F227V, H221Y, M230I, L234I, P236L og Y318F. 
Observed emergent amino acid substitutions in RT included: V106A, V106M, V106I, V108I, F227L, F227C, F227V, H221Y, M230I, L234I, P236L, and Y318F.
Forventet:  doravirin ↓ tacrolimus, sirolimus (CYP3A-induktion) 
Expected:  doravirine ↓ tacrolimus, sirolimus (Induction of CYP3A)
Croscarmellosenatrium (E468) Hypromelloseacetatsuccinat Magnesiumstearat (E470b) Mikrokrystallinsk cellulose (E460) Silica, kolloid vandfri (E551) Natriumstearylfumarat 
Croscarmellose sodium (E468) Hypromellose acetate succinate Magnesium stearate (E470b) Microcrystalline cellulose (E460) Silica, colloidal anhydrous (E551) Sodium stearyl fumarate
Tenofovirdifosfat er en svag hæmmer af DNA-polymerase α, ß og mitokondrie-DNA-polymerase γ hos pattedyr. 
Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.
Doravirins farmakokinetik er sammenlignelig hos raske forsøgspersoner og hiv-1inficerede forsøgspersoner. 
Doravirine pharmacokinetics are similar in healthy subjects and HIV-1-infected subjects.
lamivudin + tenofovirdisoproxil (300 mg lamivudin enkeltdosis + 245 mg tenofovirdisoproxil enkeltdosis, doravirin 100 mg enkeltdosis) 
lamivudine + tenofovir disoproxil (300 mg lamivudine SD + 245 mg tenofovir disoproxil SD, doravirine 100 mg SD)
Antimykobakterielle midler 
Antimycobacterials
Sedativa/hypnotika midazolam (2 mg enkeltdosis, doravirin 120 mg en gang dagligt) 
Sedatives/Hypnotics midazolam (2 mg SD, doravirine 120 mg QD)
Naturlægemidler perikon (Hypericum perforatum) 
St. John's wort (Hypericum perforatum)
Der blev ikke observeret klinisk relevante forskelle i tenofovirs farmakokinetik mellem forsøgspersoner med nedsat leverfunktion og raske forsøgspersoner. 
No clinically relevant differences in tenofovir pharmacokinetics were observed between subjects with hepatic impairment and healthy subjects.
I cellekultur, der havde sit udspring i vildtype-hiv-1 af forskellige oprindelser og undertyper såvel som NNRTI-resistent hiv-1, blev der selekteret for doravirin-resistente stammer. 
Doravirine-resistant strains were selected in cell culture starting from wild-type HIV-1 of different origins and subtypes, as well as NNRTI-resistant HIV-1.
DRV+ r + 2 NRTIer (383) 
DOR + 2 NRTIs (383) DRV+r + 2 NRTIs
Interaktion med doravirin eller doravirin/lamivudin/tenofovirdisoproxil er ikke undersøgt. 
Interaction not studied with doravirine or doravirine/lamivudine/tenofovir disoproxil.
Samtidig administration med lægemidler, der er potente CYP3A-enzyminduktorer, er kontraindiceret, da der forventes at forekomme et signifikant fald i plasmakoncentrationen af doravirin, hvilket kan nedsætte Delstrigos virkning (se pkt. 
Co-administration with medicinal products that are strong cytochrome P450 CYP3A enzyme inducers is contraindicated as significant decreases in doravirine plasma concentrations are expected to occur, which may decrease the effectiveness of Delstrigo (see sections 4.4 and 4.5).
Carnaubavoks (E903) Hypromellose (E464) Gul jernoxid (E172) Lactosemonohydrat Titandioxid (E171) Triacetin (E1518) 
Film-coating Carnauba wax (E903) Hypromellose (E464) Iron oxide yellow (E172) Lactose monohydrate Titanium dioxide (E171) Triacetin (E1518)
 doravirin AUC 0,12 (0,10; 0,15) Cmax 0,43 (0,35; 0,52) C24 0,03 (0,02; 0,04) (CYP3A-induktion) 
 doravirine AUC 0.12 (0.10, 0.15) Cmax 0.43 (0.35, 0.52) C24 0.03 (0.02, 0.04) (Induction of CYP3A)
Del (%) af forsøgspersoner med hiv-1 RNA < 40 kopier/ml med baseline-regime modtog 
Proportion (%) of Subjects With HIV-1 RNA < 40 copies/mL by Baseline Regimen Received
• Øvrige indholdsstoffer: croscarmellosenatrium (E468), hypromelloseacetatsuccinat, magnesiumstearat (E470b), mikrokrystallinsk cellulose (E460), silica, kolloid vandfri (E551) og natriumstearylfumarat. 
• The other ingredients are croscarmellose sodium E468; hypromellose acetate succinate; magnesium stearate E470b; microcrystalline cellulose E460; silica, colloidal anhydrous E551; sodium stearyl fumarate.
• kvalme, diarré, mavesmerter, opkastning, luft i maven (flatulens) 
• feeling sick (nausea), diarrhoea, stomach pain, vomiting, wind (flatulence)
Hepatitis C-antivirale midler elbasvir + grazoprevir (50 mg elbasvir en gang dagligt + 200 mg grazoprevir en gang dagligt, doravirin 100 mg en gang dagligt) 
Hepatitis C Antiviral Agents elbasvir + grazoprevir (50 mg elbasvir QD + 200 mg grazoprevir QD, doravirine 100 mg QD)
Indlægsseddel: Information til brugeren Delstrigo 100 mg/300 mg/245 mg filmovertrukne tabletter doravirin/lamivudin/tenofovirdisoproxil 
Package leaflet: Information for the user Delstrigo 100 mg/300 mg/245 mg film-coated tablets doravirine/ lamivudine/ tenofovir disoproxil
Lamivudin elimineres i mindre grad via metabolisering. 
Metabolism of lamivudine is a minor route of elimination.
Del (%) af forsøgspersoner med hiv-1 RNA < 40 kopier/ml ved baseline CD4 
Proportion (%) of Subjects With HIV-1 RNA < 40 copies/mL by Baseline CD4
Hvis administration sammen med andre moderate CYP3A-induktorer (f.eks. dabrafenib, lesinurad, bosentan, thioridazin, nafcillin, modafinil, telotristatethyl) ikke kan undgås, skal en 100 mg dosis doravirin administreres dagligt ca. 12 timer efter administration af doravirin/lamivudin/tenofovirdisoproxil (se pkt. 
If co-administration with other moderate CYP3A inducers (e.g., debrafenib, lesinurad, bosentan, thioridazine, nafcillin, modafinil, telotristat ethyl) cannot be avoided, a 100 mg dose of doravirine should be administered daily, approximately 12 hours after the administration of doravirine/lamivudine/tenofovir disoproxil dose (see section 4.2).
Opståede substitutioner i RT associeret med resistens over for doravirin inkluderede en eller flere af følgende: A98G, V106I, V106A, V106M/T, Y188L, H221Y, P225H, F227C, F227C/R og Y318Y/F. 
Emergent doravirine associated resistance substitutions in RT included one or more of the following: A98G, V106I, V106A, V106M/T, Y188L, H221Y, P225H, F227C, F227C/R, and Y318Y/F.
Hiv-1-RNA kopier/ml 
HIV-1 RNA copies/mL
Delstrigo må ikke initieres hos patienter med en estimeret CrCl på < 50 ml/min (se pkt. 
Delstrigo should not be initiated in patients with estimated CrCl < 50 mL/min (see sections 4.4 and 5.2).
Patienter, der får doravirin/lamivudin/tenofovirdisoproxil sammen med sofosbuvir/velpatasvir, skal monitoreres for bivirkninger associeret med tenofovirdisoproxil. 
Patients receiving doravirine/lamivudine/tenofovir disoproxil concomitantly with sofosbuvir/velpatasvir should be monitored for adverse reactions associated with tenofovir disoproxil.
Patienter, der får doravirin/lamivudin/tenofovirdisoproxil sammen med ledipasvir/sofosbuvir, skal monitoreres for bivirkninger associeret med tenofovirdisoproxil. 
Patients receiving doravirine/lamivudine/tenofovir disoproxil concomitantly with ledipasvir/sofosbuvir should be monitored for adverse reactions associated with tenofovir disoproxil.
Indvirkning på fertilitet 
Impairment of fertility
Tabletterne er filmovertrukket med et overtræksmaterialemed følgende indholdsstoffer: carnaubavoks (E903), hypromellose (E464), gul jernoxid (E172), lactosemonohydrat, titandioxid (E171) og triacetin (E1518). 
The tablets are film-coated with a coating material containing the following ingredients: carnauba wax E903, hypromellose E464; iron oxide yellow E172; lactose monohydrate; titanium dioxide E171; and triacetin E1518.
Doravirin skal ordineres med forsigtighed sammen med lægemidler, der kan nedsætte eksponeringen for doravirin (se pkt. 
Caution should be given to prescribing doravirine with medicinal products that may reduce the exposure of doravirine (see sections 4.3 and 4.5).
Hvis doravirin/lamivudin/tenofovirdisoproxil administreres samtidigt med rifabutin, skal en 100 mg dosis doravirin tages dagligt ca. 12 timer efter dosis af doravirin/lamivudin/tenofovirdisoproxil. 
If doravirine/ lamivudine/ tenofovir disoproxil is coadministered with rifabutin, a 100 mg dose of doravirine should be taken daily, approximately 12 h after dose of doravirine/lamivudine/tenofovir disoproxil.
Anbefalinger vedrørende administration sammen med doravirin/lamivudin/tenofovirdisoproxil ledipasvir + sofosbuvir (90 mg ledipasvir enkeltdosis + 
Recommendation Concerning Co-administration with doravirine/lamivudine/tenofo vir disoproxil ledipasvir + sofosbuvir (90 mg ledipasvir SD + 400 mg sofosbuvir SD, doravirine 100 mg SD)
Hiv-1 RNA ≥ 40 kopier/ml 
HIV-1 RNA ≥ 40 copies/mL
• Aktive stoffer: 100 mg doravirin, 300 mg lamivudin og 245 mg tenofovirdisoproxil (som fumarat). 
• The active substances are 100 mg of doravirine, 300 mg of lamivudine and 245 mg of tenofovir disoproxil (as fumarate)
flatulens 
flatulence
Mave-tarm-kanalen Almindelig kvalme, diarré, abdominalsmerter 
Gastrointestinal disorders Common nausea, diarrhoea, abdominal pain 4, vomiting,
Lamivudin Lamivudin havde ingen indvirkning på fertiliteten hos han- eller hunrotter. 
Lamivudine Lamivudine did not affect male or female fertility in rats.
Samtidig administration af doravirin/lamivudin/tenofovirdisoproxil og andre moderate CYP3Ainduktorer er ikke vurderet, men der forventes en nedsat koncentration af doravirin. 
Co-administration of doravirine/lamivudine/tenofovir disoproxil with other moderate CYP3A inducers has not been evaluated, but decreased doravirine concentrations are expected.
Kinasehæmmere dabrafenib 
Kinase Inhibitors dabrafenib
• nedsat indhold af fosfat 
• decreased levels phosphate
Hiv-1 RNA < 40 kopier/ml 
HIV-1 RNA < 40 copies/mL
norgestimat/ethinylestradiol 
norgestimate/ethinyl oestradiol
Tag ikke Delstrigo 
Do not run out of Delstrigo.
Doravirin er ikke undersøgt hos forsøgspersoner med svært nedsat leverfunktion (Child-Pugh-score C) (se pkt. 
Doravirine has not been studied in subjects with severe hepatic impairment (Child-Pugh score C) (see section 4.2).
 doravirin AUC 3,06 (2,85; 3,29) Cmax 1,25 (1,05; 1,49) C24 2,75 (2,54; 2,98) (CYP3A-hæmning) 
 doravirine AUC 3.06 (2.85, 3.29) Cmax 1.25 (1.05, 1.49) C24 2.75 (2.54, 2.98) (Inhibition of CYP3A)
Udtræden af studiet på grund af bivirkninger 
Discontinuation due to adverse events
Delstrigo indeholder lactosemonohydrat og må ikke anvendes til patienter med arvelig galactoseintolerans, total lactasemangel eller glucose/galactosemalabsorption. 
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Lever og galdeveje Sjælden fedtlever*, hepatitis* 
Hepatobiliary disorders Rare hepatic steatosis*, hepatitis*
Midler mod diarré telotristatethyl 
Antidiarrhoeals telotristat ethyl
• lamivudin - en nukleosidanalog revers transkriptasehæmmer (NRTI) 
• Lamivudine - a nucleoside analogue reverse transcriptase inhibitor (NRTI)
• bosentan (et lægemiddel til behandling af lungesygdom) 
• bosentan (a medicine to treat lung disease)
 doravirin AUC 1,15 (1,07; 1,24) Cmax 1,11 (0,97; 1,27) C24 1,24 (1,13; 1,36) 
↑ doravirine AUC 1.15 (1.07, 1.24) Cmax 1.11 (0.97, 1.27) C24 1.24 (1.13, 1.36)
• nedsat indhold af kalium i blodet 
• decreased levels of potassium in your blood
På baggrund af en farmakokinetisk populationsanalyse af doravirin hos raske og hiv-1-inficerede forsøgspersoner er der ikke identificeret klinisk relevante racemæssige forskelle i doravirins farmakokinetik. 
No clinically relevant racial differences in the pharmacokinetics of doravirine have been identified based on a population pharmacokinetic analysis of doravirine in healthy and HIV-1-infected subjects.
• lesinurad (et lægemiddel til behandling af urinsyregigt) 
• lesinurad (a medicine to treat gout)
Sjælden brystsmerter, kuldegysninger, smerter, tørst 
Rare chest pain, chills, pain, thirst
 doravirin AUC 1,56 (1,45; 1,68) Cmax 1,41 (1,25; 1,58) C24 1,61 (1,45; 1,79) (CYP3A-hæmning) 
 doravirine AUC 1.56 (1.45, 1.68) Cmax 1.41 (1.25, 1.58) C24 1.61 (1.45, 1.79) (Inhibition of CYP3A)
• tenofovirdisoproxil - en nukleosidanalog revers transkriptasehæmmer (NRTI). 
• Tenofovir disoproxil - a nucleoside analogue reverse transcriptase inhibitor (NRTI)
 doravirin AUC 0,50 (0,45; 0,55) Cmax 0,99 (0,85; 1,15) C24 0,32 (0,28; 0,35) (CYP3A-induktion) 
 doravirine AUC 0.50 (0.45, 0.55) Cmax 0.99 (0.85, 1.15) C24 0.32 (0.28, 0.35) (Induction of CYP3A)
0,03 mg ethinylestradiol/ 0,15 mg levonorgestrel enkeltdosis, doravirin 100 mg en gang dagligt 
0.03 mg ethinyl oestradiol/ 0.15 mg levonorgestrel SD, doravirine 100 mg QD
Når Delstrigo administreres sammen med rifabutin, skal en 100 mg dosis doravirin gives dagligt ca. 12 timer efter administration af doravirin/lamivudin/tenofovirdisoproxil (se pkt. 
When Delstrigo is co-administered with rifabutin, a 100 mg dose of doravirine should be given daily, approximately 12 hours after doravirine/lamivudine/tenofovir disoproxil dose (see section 4.2).
Hver filmovertrukken tablet indeholder 100 mg doravirin, 300 mg lamivudin og 300 mg tenofovirdisoproxilfumarat svarende til 245 mg tenofovirdisoproxil. 
Each film-coated tablet contains 100 mg of doravirine, 300 mg of lamivudine, and 300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil.
Opioidanalgetika methadon (Individualiseret dosis på 20-200 mg en gang dagligt, doravirin 100 mg en gang dagligt) 
Opioid Analgesics methadone (20-200 mg QD individualised dose, doravirine 100 mg QD)
Doravirin udskilles i mindre grad via nyrerne. 
Renal excretion of doravirine is minor.
Forventet:  doravirin (CYP3A-hæmning grundet ritonavir) 
Expected:  doravirine (Inhibition of CYP3A due to ritonavir)
Anbefalinger vedrørende administration sammen med doravirin/lamivudin/tenofovirdisoproxil ribavirin 
Recommendation Concerning Co-administration with doravirine/lamivudine/tenofo vir disoproxil
Hver filmovertrukken tablet indeholder 100 mg doravirin, 300 mg lamivudin og 245 mg tenofovirdisoproxil. 
Each film-coated tablet contains 100 mg of doravirine, 300 mg of lamivudine and 245 mg of tenofovir disoproxil.
Hvis samtidig administration ikke kan undgås, skal en 100 mg dosis doravirin tages dagligt ca. 12 timer efter dosis af doravirin/lamivudin/tenofovirdisoproxil. 
If co-administration cannot be avoided, a 100 mg dose of doravirine should be taken daily, approximately 12 h after the dose of doravirine/lamivudine/tenofovir disoproxil.
Sådan skal du tage Delstrigo 
How to take Delstrigo
• nedsat indhold af blodplader i blodet (øget blødningstendens) 
• decreased levels of platelets in your blood (you may bleed more easily)
• koncentrationsbesvær, hukommelsesproblemer, prikken og snurren i hænder og fødder, 
• trouble concentrating, memory problems, tingling of hands and feet, stiff muscles, poor quality of sleep
• forhøjet indhold af leverenzymer (ASAT) 
• increased levels in liver enzymes (AST)
4.4 og 5.2 for oplysninger om potentielle lægemiddelinteraktioner med tenofovirdisoproxil eller lamivudin. 
For potential medicine product interactions with tenofovir disoproxil or lamivudine, (see sections 4.4 and 5.2).
Er du i tvivl, så spørg lægen, apotekspersonalet eller sygeplejersken. 
• If you have any further questions, ask your doctor, pharmacist, or nurse.
5.2), kan samtidig administration af doravirin/lamivudin/tenofovirdisoproxil og lægemidler, der nedsætter nyrefunktionen eller konkurrerer om aktiv tubulær sekretion via OAT1, OAT3 eller MRP4, øge serumkoncentrationen af tenofovir. 
Because tenofovir is primarily eliminated by the kidneys through a combination of glomerular filtration and active tubular secretion (see section 5.2), co-administration of doravirine/lamivudine/tenofovir disoproxil with medicinal products that reduce renal function or compete for active tubular secretion via OAT1, OAT3 or MRP4 may increase serum concentrations of tenofovir.
fordøjelsesproblemer, blød afføring, mavekramper, hyppig afføring, betændelse i bugspytkirtlen 
indigestion, soft stools, stomach spasms, frequent bowel movements, inflammation of the pancreas (pancreatitis) (causing stomach pain, vomiting)
• mareridt, depression, angst, irritabilitet, forvirring, selvmordstanker 
Uncommon: may affect up to 1 in 100 people: • nightmares, depression, anxiety, irritability, confusion, suicidal thoughts
Doravirin 
Doravirine
 doravirin 
 doravirine
Antidiabetika metformin (1.000 mg enkeltdosis, doravirin 100 mg en gang dagligt) 
Antidiabetics metformin (1000 mg SD, doravirine 100 mg QD)
*AUC0- for enkeltdosis, AUC0-24 for en gang dagligt. 
 = increase, ↓ = decrease, ↔ = no change CI = Confidence Interval; SD = Single Dose; QD = Once Daily; BID = Twice Daily *AUC0- for single dose, AUC0-24 for once daily.
NRTI-baggrundsbehandling 
NRTI background therapy
Enkeltdosis rifampicin (600 mg enkeltdosis, doravirin 100 mg enkeltdosis) 
Single dose rifampicin (600 mg SD, doravirine 100 mg SD)
Det skal du vide, før du begynder at tage Delstrigo Sådan skal du tage Delstrigo Bivirkninger 
What Delstrigo is and what it is used for What you need to know before you take Delstrigo How to take Delstrigo
 lamivudin AUC 0,94 (0,88; 1,00) Cmax 0,92 (0,81; 1,05) 
lamivudine AUC 0.94 (0.88, 1.00) Cmax 0.92 (0.81, 1.05)
Hiv-antivirale midler tenofovirdisoproxil (300 mg en gang dagligt, doravirin 100 mg enkeltdosis) 
HIV Antiviral Agents tenofovir disoproxil (300 mg QD, doravirine 100 mg SD)
Ikke almindelig asteni, utilpashed 
Uncommon asthenia, malaise
 doravirin AUC 0,83 (0,76; 0,91) Cmax 0,88 (0,76; 1,01) C24 0,84 (0,77; 0,92) 
 doravirine AUC 0.83 (0.76, 0.91) Cmax 0.88 (0.76, 1.01) C24 0.84 (0.77, 0.92)
rifabutin (300 mg en gang dagligt, doravirin 100 mg enkeltdosis) 
rifabutin (300 mg QD, doravirine 100 mg SD)
Tørremidlet må ikke fjernes. 
Do not remove the desiccant.
 doravirin AUC 0,95 (0,80; 1,12) Cmax 0,80 (0,64; 1,01) C24 0,94 (0,78; 1,12) 
 doravirine AUC 0.95 (0.80, 1.12) Cmax 0.80 (0.64, 1.01) C24 0.94 (0.78, 1.12)